Literature DB >> 21586309

Subchronic toxicity studies with ginsenoside compound K delivered to dogs via intravenous administration.

Y L Gao1, Z F Liu, C M Li, J Y Shen, H X Yin, G S Li.   

Abstract

Compound K, i.e., 20-O-β-d-glucopyranosyl-20(S)-protopanaxadiol, is the main metabolite of the protopanaxadiol type of ginseng saponin produced by intestinal bacteria after oral administration of ginseng extract. In the present study, the toxicity of compound K was evaluated in male and female dogs after 90 days continuous intravenous infusion. Beagle dogs were treated with compound K at doses of 6.7, 20 and 60 mg/kg/day, and observed for 90 days followed by recovery periods. Measurements included clinical observations, body weight, food consumption, temperature, electrocardiogram (ECG), hematology, blood chemistry, urinalysis, gross necropsy, organ weight and histopathology. Under the conditions, the clinical condition of the animals, body weights, body weight gains and food consumption were unaffected by compound K administration relative to the control group. Hematology, ECG data and urinalysis parameters were also unaffected. However, the hepatotoxicity was evident from the observation of multiple parameters, including histopathological evaluation of liver tissue upon necropsy as well as large increases in plasma levels of liver enzymes (alanine aminotransferase, ALT, Gamma-glutamyltranspeptidase, γ-GT, alkaline phosphatase,ALP) in groups receiving compound K (20 or 60 mg/kg/day), and this hepatoxicity might be reversible. In addition, the NOAEL of compound K is 6.7 mg/kg/day in this 90 days toxicity study.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21586309     DOI: 10.1016/j.fct.2011.05.003

Source DB:  PubMed          Journal:  Food Chem Toxicol        ISSN: 0278-6915            Impact factor:   6.023


  11 in total

1.  Ginsenoside metabolite compound K enhances the efficacy of cisplatin in lung cancer cells.

Authors:  Yang Li; Tong Zhou; Chengyuan Ma; Weiwei Song; Jian Zhang; Zhenxiang Yu
Journal:  J Thorac Dis       Date:  2015-03       Impact factor: 2.895

Review 2.  Pharmacological properties of ginsenosides in inflammation-derived cancers.

Authors:  Do Luong Huynh; Nguyen Hoai Nguyen; Cuong Thach Nguyen
Journal:  Mol Cell Biochem       Date:  2021-04-26       Impact factor: 3.396

3.  Characterization of hyperglycemia due to sub-chronic administration of red ginseng extract via comparative global proteomic analysis.

Authors:  Ann-Yae Na; Jung Jae Jo; Oh Kwang Kwon; Piljoung Cho; Yan Gao; Ju-Hyun Kim; Kyu Min Kim; Sung Hwan Ki; Sangkyu Lee
Journal:  Sci Rep       Date:  2021-06-11       Impact factor: 4.379

Review 4.  Pharmacological effects of ginseng on infectious diseases.

Authors:  Nguyen H Nguyen; Cuong Thach Nguyen
Journal:  Inflammopharmacology       Date:  2019-08-12       Impact factor: 5.093

Review 5.  Review of cases of patient risk associated with ginseng abuse and misuse.

Authors:  Doo Jin Paik; Chang Ho Lee
Journal:  J Ginseng Res       Date:  2014-12-06       Impact factor: 6.060

6.  Compound K Attenuates the Development of Atherosclerosis in ApoE(-/-) Mice via LXRα Activation.

Authors:  Li Zhou; Yu Zheng; Zhuoying Li; Lingxia Bao; Yin Dou; Yuan Tang; Jianxiang Zhang; Jianzhi Zhou; Ya Liu; Yi Jia; Xiaohui Li
Journal:  Int J Mol Sci       Date:  2016-07-08       Impact factor: 5.923

7.  Enhanced antidiabetic efficacy and safety of compound K⁄β-cyclodextrin inclusion complex in zebrafish.

Authors:  Youn Hee Nam; Hoa Thi Le; Isabel Rodriguez; Eun Young Kim; Keonwoo Kim; Seo Yule Jeong; Sang Ho Woo; Yeong Ro Lee; Rodrigo Castañeda; Jineui Hong; Min Gun Ji; Ung-Jin Kim; Bin Na Hong; Tae Woo Kim; Tong Ho Kang
Journal:  J Ginseng Res       Date:  2016-08-23       Impact factor: 6.060

8.  Intravenous and subcutaneous toxicity and absorption kinetics in mice and dogs of the antileishmanial triterpene saponin PX-6518.

Authors:  Louis Maes
Journal:  Molecules       Date:  2013-04-22       Impact factor: 4.411

9.  Ginsenoside compound K protects human umbilical vein endothelial cells against oxidized low-density lipoprotein-induced injury via inhibition of nuclear factor-κB, p38, and JNK MAPK pathways.

Authors:  Shan Lu; Yun Luo; Ping Zhou; Ke Yang; Guibo Sun; Xiaobo Sun
Journal:  J Ginseng Res       Date:  2017-10-16       Impact factor: 6.060

10.  Acute and repeated dose 26-week oral toxicity study of 20(S)-ginsenoside Rg3 in Kunming mice and Sprague-Dawley rats.

Authors:  Chunmei Li; Zhezhe Wang; Guisheng Li; Zhenhua Wang; Jianrong Yang; Yanshen Li; Hongtao Wang; Haizhu Jin; Junhua Qiao; Hongbo Wang; Jingwei Tian; Albert W Lee; Yonglin Gao
Journal:  J Ginseng Res       Date:  2018-10-19       Impact factor: 6.060

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.